|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/8/2007 1:17:29 PM
WAKEFIELD, Mass.--(BUSINESS WIRE)--Implant Sciences Corporation (AMEX: IMX) a developer and manufacturer of products for national security, semiconductor and medical industries, announced today its understanding that CorNova Inc. (“CorNova”), a privately-held company focused on the development and marketing of innovative endovascular diagnostics and treatments, has sold approximately 75,000 shares of Implant’s common stock over the past two (2) days through its broker. In March 2004 and February 2005, CorNova acquired approximately 87,000 shares, in the aggregate, of Implant’s common stock in connection with (i) the capitalization of CorNova in March 2004 and (ii) the successful completion of a financing by CorNova in February 2005. The Company understands that the liquidation of Implant’s common stock by CorNova is to provide funding for CorNova’s working capital. CorNova continues to hold approximately 12,000 shares of Implant’s common stock, whose disposition we believe is imminent.
|
|
|
|
|
|
|
|
|
|
|